Several key components of parathyroid gland function have yet to be fully characterized in chronic renal failure despite the central role of disturbances in parathyroid hormone (PTH) secretion in the pathogenesis of renal osteodystrophy. It is not known, therefore, whether the normal diurnal variations in serum ionized calcium and PTH levels are preserved in renal failure or whether pulsatile PTH secretion is maintained in either secondary hyperparathyroidism or adynamic renal osteodystrophy. Both factors may contribute to substantial short-term fluctuations in serum PTH levels in patients with end-stage renal disease. Because serum intact PTH measurements are widely used not only for the diagnosis of renal osteodystrophy but also to monitor therapy, disturbances in diurnal PTH secretion and/or pulsatile PTH release may serve as important modifiers of PTH secretion and of bone formation and turnover in chronic renal failure; such changes may directly affect the development and progression of selected types of renal osteodystrophy. To address these issues, cosinor analysis and deconvolution analysis will be used to assess diurnal PTH secretion and pulsatile PTH release in patients with secondary hyperparathyroidism, in those with adynamic renal osteodystrophy and in subjects with normal renal and parathyroid gland function. The impact of daily oral and thrice weekly intermittent oral doses of calcitriol on diurnal PTH secretion and pulsatile PTH release in patients with secondary hyperparathyroidism will also be evaluated, and the respective roles of hemodialysis and peritoneal dialysis as separate modifiers of diurnal and pulsatile PTH secretion in end-stage renal disease will be examined.
The specific aims of the current proposal are: 1) To measure and compare the diurnal variations in serum ionized calcium and PTH levels in patients with secondary hyperparathyroidism and adynamic renal osteodystrophy; 2) To measure and compare the components of pulsatile PTH secretion in patients with secondary hyperparathyroidism and adynamic renal osteodystrophy; 3) To determine whether continuous or intermittent calcitriol dosage regimens diminish or eliminate pulsatile PTH secretion and alter the diurnal patterns of ionized calcium and PTH in secondary hyperparathyroidism. The results of the studies proposed should provide new information about the regulation of PTH secretion in chronic renal failure, and they should also offer new insights into additional mechanisms that contribute to the pathogenesis of specific types of renal osteodystrophy.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
1R01DK052905-01A1
Application #
2599675
Study Section
General Medicine B Study Section (GMB)
Project Start
1998-08-01
Project End
2002-05-31
Budget Start
1998-08-01
Budget End
1999-05-31
Support Year
1
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Goodman, William G (2004) Calcium-sensing receptors. Semin Nephrol 24:17-24
Goodman, William G (2003) Medical management of secondary hyperparathyroidism in chronic renal failure. Nephrol Dial Transplant 18 Suppl 3:iii2-8
Goodman, William G; Juppner, Harald; Salusky, Isidro B et al. (2003) Parathyroid hormone (PTH), PTH-derived peptides, and new PTH assays in renal osteodystrophy. Kidney Int 63:1-11
Goodman, William G (2003) Assays for parathyroid hormone and their use in patients with end-stage renal disease. Blood Purif 21:118-23
Goodman, William G (2002) Calcimimetic agents and secondary hyperparathyroidism: treatment and prevention. Nephrol Dial Transplant 17:204-7
Goodman, William G; Turner, Stewart A (2002) Future role of calcimimetics in end-stage renal disease. Adv Ren Replace Ther 9:200-8
Goodman, William G (2002) Vascular calcification in end-stage renal disease. J Nephrol 15 Suppl 6:S82-5
Salusky, Isidro B; Goodman, William G (2002) Cardiovascular calcification in end-stage renal disease. Nephrol Dial Transplant 17:336-9
Goodman, William G; Salusky, Isidro B; Juppner, Harald (2002) New lessons from old assays: parathyroid hormone (PTH), its receptors, and the potential biological relevance of PTH fragments. Nephrol Dial Transplant 17:1731-6
Goodman, William G; Hladik, Gerald A; Turner, Stewart A et al. (2002) The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 13:1017-24

Showing the most recent 10 out of 18 publications